Calcium Channel Blockers for Hypertension
For uncomplicated hypertension, start with a long-acting dihydropyridine calcium channel blocker—specifically amlodipine 5 mg once daily—as it provides 24-hour blood pressure control with proven cardiovascular outcomes and is well-tolerated. 1
First-Line CCB Selection
Recommended Agents
Long-acting dihydropyridine CCBs are the preferred calcium channel blockers for hypertension treatment 1, 2:
- Amlodipine: 5-10 mg once daily (most evidence-based choice) 3, 4
- Felodipine: 5-10 mg once daily 3
- Nifedipine extended-release: 30-90 mg once daily 3
Critical Distinction: Avoid Short-Acting Formulations
Never use immediate-release nifedipine for chronic hypertension management unless combined with a beta-blocker, as it causes reflex sympathetic activation and increased adverse cardiovascular events 3, 5. Short-acting dihydropyridines have "increased adverse potential" and must be avoided in the absence of concomitant beta blockade 3.
Starting Doses and Titration
Initial Dosing
- Amlodipine: Start 5 mg once daily, titrate to 10 mg if needed 3
- Felodipine: Start 5 mg once daily, titrate to 10 mg 3
- Nifedipine SR: Start 30 mg once daily, titrate to 180 mg 3
Special Populations
- Elderly patients: Use more gradual dose titration due to increased risk of adverse effects, particularly in frail individuals 2
- Patients with left ventricular dysfunction: Amlodipine and felodipine are reasonably well tolerated in mild LV dysfunction 3
Non-Dihydropyridine CCBs
Verapamil and diltiazem are alternative options but have important contraindications 3:
- Verapamil: 120-480 mg once daily (slow-release formulation)
- Diltiazem: 120-360 mg once daily (slow-release formulation)
Avoid verapamil and diltiazem in patients with:
- Pulmonary edema
- Severe left ventricular dysfunction
- Heart failure with reduced ejection fraction 3
Exercise caution when combining non-dihydropyridine CCBs with beta-blockers due to additive effects on AV conduction and heart rate 1, 6.
Combination Therapy Strategy
When monotherapy fails to achieve blood pressure targets:
Preferred combinations 1:
- CCB + ACE inhibitor (Grade C evidence)
- CCB + ARB (Grade D evidence)
- Thiazide diuretic + dihydropyridine CCB (Grade B evidence—strongest combination evidence)
Avoid combining:
- Non-dihydropyridine CCB + beta-blocker (Grade D—risk of bradycardia and AV block) 1
Monitoring Considerations
Blood Pressure Monitoring
- Target: <130/80 mmHg for most patients 7, 8
- Elderly patients (≥80 years): Target <150 mmHg systolic may be acceptable 6
- Monitor blood pressure in both sitting and standing positions in elderly patients due to increased postural hypotension risk 2
Common Side Effects to Monitor
- Peripheral edema (most common with dihydropyridines): 5-10% incidence 3
- Headache: Particularly during initial titration 3
- Flushing and dizziness: More common with immediate-release formulations 3
- Constipation: More common with verapamil 3
Laboratory Monitoring
- Baseline: Serum creatinine, electrolytes
- Follow-up: No specific laboratory monitoring required for CCBs alone
- If combined with diuretics or RAS blockers: Monitor potassium and renal function
Clinical Pitfalls to Avoid
Do not use immediate-release nifedipine for chronic hypertension—it increases cardiovascular risk 3, 5
Do not combine non-dihydropyridine CCBs with beta-blockers without careful consideration—risk of severe bradycardia and heart block 1
Do not use verapamil or diltiazem in heart failure with reduced ejection fraction—they worsen outcomes 3
Peripheral edema management: If edema develops, consider adding an ACE inhibitor or ARB rather than discontinuing the CCB, as RAS blockers reduce CCB-induced edema 9
Elderly patients: Start low and titrate slowly to avoid precipitous blood pressure drops and orthostatic hypotension 2
Evidence-Based Rationale
The 2015 Canadian Hypertension Education Program guidelines provide Grade A evidence for long-acting dihydropyridine CCBs in isolated systolic hypertension and Grade B evidence for diastolic/systolic hypertension 1. The European Society of Hypertension 2007 guidelines confirm that dihydropyridine CCBs reduce cardiovascular morbidity and mortality in elderly patients with both systolic-diastolic and isolated systolic hypertension 2. Recent meta-analyses demonstrate that amlodipine-based therapy is at least as effective as, and sometimes superior to, diuretics and beta-blockers in preventing target organ damage 9, 10.